Evidence map›Paper›PMID 31168692›Full record

ArticleBreast cancer (Tokyo, Japan)2019

Correction to: Neutropenia management with palbociclib in Japanese patients with advanced breast cancer.

Norikazu Masuda, Hirofumi Mukai, Kenichi Inoue, Yoshiaki Rai, Shinji Ohno, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Yoshiko Umeyama, Hiroji Iwata and 1 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Norikazu MasudaDepartment of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, 2-1-14, Hoenzaka, Chuou-ku, Osaka, 540-0006, Japan. nmasuda@alpha.ocn.ne.jp.
Hirofumi MukaiDepartment of Breast and Medical Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa-shi, Chiba, 277-8577, Japan.
Kenichi InoueDivision of Breast Oncology, Saitama Cancer Center, 780 Komuro Inamachi Kitaadachi-gun, Saitama, 362-0806, Japan.
Yoshiaki RaiSagara Hospital, 3-28 Tenokuchi-cho, Kagoshima City, 892-0845, Japan.
Shinji OhnoBreast Oncology Center, The Cancer Institute Hospital of JFCR, 3-8-31, Ariake, Koto-ku, Tokyo, 135-8550, Japan.
Yuko MoriPfizer Japan Inc, Tokyo, Japan.
Satoshi HashigakiPfizer Japan Inc, Tokyo, Japan.
Yasuaki MuramatsuPfizer Japan Inc, Tokyo, Japan.
Yoshiko UmeyamaPfizer Japan Inc, Tokyo, Japan.
Hiroji IwataDepartment of Breast Oncology, Aichi Cancer Center Hospital, 1-1, Kanokoden, Chikusa-ku, Nagoya, Aichi, 464-8681, Japan.
Masakazu ToiKyoto University Graduate School of Medicine, 54 Kawaracho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The correct name of the last author should be "Masakazu Toi", and not ''Masakuzu Toi" as given in the original publication of the article.

Identifiers

PMID31168692
PMCPMC6828135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.